P. gingivalis / gingipain (antimicrobial)

Class

Antimicrobial targeting P. gingivalis-positive Alzheimer's

The target here is the gingipain family, a group of protein-cutting enzymes (cysteine proteases) secreted by Porphyromonas gingivalis, a bacterium strongly associated with chronic gum disease. These enzymes allow the bacterium to break down host proteins for nutrients, disable local immune defenses, and destroy the tissue that holds teeth in place. Beyond the mouth, gingipains have been detected in brain tissue, which has led to a hypothesis connecting long-standing P. gingivalis infection to neurodegenerative disease, particularly Alzheimer's disease. Under this hypothesis, bacteria or their secreted enzymes may reach the brain through the bloodstream, where gingipains can damage neurons directly by cutting structural and functional proteins, and can trigger inflammatory responses that may accelerate processes such as amyloid and tau accumulation. Small-molecule inhibitors designed to block gingipain enzymatic activity aim to neutralize this specific virulence factor and limit its downstream neurotoxic effects, rather than simply killing the bacterium the way a conventional antibiotic would. This mechanism sits at the intersection of periodontal microbiology and neurodegeneration research, reflecting broader scientific interest in how chronic microbial exposure may contribute to inflammatory and degenerative disease outside the site of original infection.